Personalized Cancer Medicine: From Molecular Diagnostics to Targeted Therapy with Natural Products

Publication type:
Journal article
Metadata:
Autoren
  • Thomas Efferth
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000280370900012&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1055/s-0030-1249937
eISSN
1439-0221
Externe Identifier
  • Clarivate Analytics Document Solution ID: 631TK
  • PubMed Identifier: 20486071
ISSN
0032-0943
Ausgabe der Veröffentlichung
11
Zeitschrift
PLANTA MEDICA
Schlüsselwörter
  • chemotherapy
  • comparative genomic
  • hybridization
  • drug resistance
  • pharmacogenomics
  • pharmacognosy
  • traditional Chinese medicine
Paginierung
1143 - 1154
Datum der Veröffentlichung
2010
Status
Published
Titel
Personalized Cancer Medicine: From Molecular Diagnostics to Targeted Therapy with Natural Products
Sub types
  • Review
Ausgabe der Zeitschrift
76

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
  • Thomas Efferth
DOI
10.1055/s-0030-1249937
eISSN
1439-0221
ISSN
0032-0943
Ausgabe der Veröffentlichung
11
Zeitschrift
Planta Medica
Sprache
en
Online publication date
2010
Paginierung
1143 - 1154
Datum der Veröffentlichung
2010
Status
Published
Herausgeber
Georg Thieme Verlag KG
Herausgeber URL
http://dx.doi.org/10.1055/s-0030-1249937
Datum der Datenerfassung
2017
Titel
Personalized Cancer Medicine: From Molecular Diagnostics to Targeted Therapy with Natural Products
Ausgabe der Zeitschrift
76

Data source: Crossref

Abstract
Personalized cancer medicine aims to develop individualized treatment options adapted to factors relevant for the prognosis of each patient. Molecular biomarkers are required to predict the likelihood of an individual tumor's responsiveness or of toxicity in normal organs and to advise optimized treatments with improved efficacy at reduced side effects for each cancer patient. In the present review, we present a concept, which takes advantage of methods of molecular diagnostics to identify predictive markers at the DNA, mRNA, and protein levels. Markers with prognostic value concerning treatment response and patient survival can then be used as targets to develop optimized drugs. We focus on three examples to illustrate this strategy: (i) chemoselective treatment of tumors with 9p21 deletion by L-alanosine, (ii) treatment of multidrug-resistant P-glycoprotein-expressing tumor cells by non-cross-resistant natural products or by inhibitors of P-glycoprotein to overcome multidrug resistance, and (iii) natural products that inhibit the epidermal growth factor receptor (EGFR) in EGFR-overexpressing tumor cells.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany. efferth@uni-mainz.de
Autoren
DOI
10.1055/s-0030-1249937
eISSN
1439-0221
Externe Identifier
  • PubMed Identifier: 20486071
Open access
false
ISSN
0032-0943
Ausgabe der Veröffentlichung
11
Zeitschrift
Planta medica
Schlüsselwörter
  • Humans
  • Neoplasms
  • Alanine
  • RNA, Messenger
  • Antibiotics, Antineoplastic
  • Biological Products
  • Phytotherapy
  • Cytogenetics
  • Drug Resistance, Neoplasm
  • Genetic Variation
  • ErbB Receptors
  • Biomarkers, Tumor
  • Precision Medicine
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
Sprache
eng
Medium
Print-Electronic
Online publication date
2010
Paginierung
1143 - 1154
Datum der Veröffentlichung
2010
Status
Published
Datum der Datenerfassung
2010
Titel
Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products.
Sub types
  • Review
  • Journal Article
Ausgabe der Zeitschrift
76

Data source: Europe PubMed Central

Abstract
Personalized cancer medicine aims to develop individualized treatment options adapted to factors relevant for the prognosis of each patient. Molecular biomarkers are required to predict the likelihood of an individual tumor's responsiveness or of toxicity in normal organs and to advise optimized treatments with improved efficacy at reduced side effects for each cancer patient. In the present review, we present a concept, which takes advantage of methods of molecular diagnostics to identify predictive markers at the DNA, mRNA, and protein levels. Markers with prognostic value concerning treatment response and patient survival can then be used as targets to develop optimized drugs. We focus on three examples to illustrate this strategy: (i) chemoselective treatment of tumors with 9p21 deletion by L-alanosine, (ii) treatment of multidrug-resistant P-glycoprotein-expressing tumor cells by non-cross-resistant natural products or by inhibitors of P-glycoprotein to overcome multidrug resistance, and (iii) natural products that inhibit the epidermal growth factor receptor (EGFR) in EGFR-overexpressing tumor cells.
Autoren
  • Thomas Efferth
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/20486071
DOI
10.1055/s-0030-1249937
eISSN
1439-0221
Ausgabe der Veröffentlichung
11
Zeitschrift
Planta Med
Schlüsselwörter
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Alanine
  • Antibiotics, Antineoplastic
  • Biological Products
  • Biomarkers, Tumor
  • Cytogenetics
  • Drug Resistance, Neoplasm
  • ErbB Receptors
  • Genetic Variation
  • Humans
  • Neoplasms
  • Phytotherapy
  • Precision Medicine
  • RNA, Messenger
Sprache
eng
Country
Germany
Paginierung
1143 - 1154
Datum der Veröffentlichung
2010
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2010
Titel
Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products.
Sub types
  • Journal Article
  • Review
Ausgabe der Zeitschrift
76

Data source: PubMed

Beziehungen:
Property of

Tools